- Conditions
- Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Mosunetuzumab, Positron Emission Tomography, Questionnaire Administration
- Procedure · Biological · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 333
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rheumatoid Arthritis
- Interventions
- Rituximab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- DI-Leu16-IL2 immunocytokine, rituximab, flow cytometry, immunohistochemistry staining method, pharmacological study, laboratory biomarker analysis, enzyme-linked immunosorbent assay, reverse transcriptase-polymerase chain reaction
- Biological · Other · Genetic
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Interventions
- Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, Nivolumab, Prednisone, Quality-of-Life Assessment, Rituximab
- Drug · Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Bulky Disease, Fatigue, Fever, Grade 3a Follicular Lymphoma, Night Sweats, Splenomegaly, Weight Loss
- Interventions
- Lenalidomide, Obinutuzumab
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-Cell
- Interventions
- Tafasitamab, Polatuzumab vedotin, Glofitamab, Obinutuzumab
- Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
- Interventions
- Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography, Etoposide, Magnetic Resonance Imaging, Mosunetuzumab, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Vincristine
- Procedure · Drug · Biological
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Ublituximab, Umbralisib, Venetoclax
- Drug
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 45 more
- Conditions
- Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
- Interventions
- alemtuzumab, ofatumumab, biopsy
- Biological · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- AME-133v (LY2469298)
- Biological
- Lead sponsor
- Applied Molecular Evolution
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stanford, California + 8 more
- Conditions
- AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma
- Interventions
- rituximab, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan, peripheral blood stem cell transplantation, filgrastim, laboratory biomarker analysis
- Biological · Radiation · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE
- Interventions
- AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab
- Drug
- Lead sponsor
- Artiva Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Tucson, Arizona • San Diego, California + 6 more
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Avelumab, Carboplatin, Etoposide Phosphate, Ibrutinib, Ifosfamide, Laboratory Biomarker Analysis, Rituximab, Utomilumab
- Procedure · Drug · Other + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Carboplatin, Etoposide, Filgrastim, Ifosfamide, Leukapheresis, Plerixafor, Rituximab
- Drug · Biological · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
- Interventions
- FT596, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab, Bendamustine
- Drug
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Minneapolis, Minnesota • St Louis, Missouri + 5 more
- Conditions
- Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone, Rituximab, Vincristine Sulfate, Zanubrutinib
- Drug · Biological
- Lead sponsor
- Yazeed Sawalha
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- Cleveland, Ohio • Columbus, Ohio • Charleston, South Carolina
- Conditions
- Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
- Interventions
- Acalabrutinib, Obinutuzumab, Venetoclax
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Oncology Patients Receiving Chemotherapy
- Interventions
- Cetirizine HCl 10 mg/mL, Diphenhydramine 50 mg/mL, anti-CD20 such as Rituximab or Paclitaxel
- Drug
- Lead sponsor
- TerSera Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 7
- States / cities
- Napa, California • Rancho Mirage, California • Santa Rosa, California + 4 more
- Conditions
- Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma
- Interventions
- rituximab, ibritumomab tiuxetan, anti-thymocyte globulin, total nodal irradiation, peripheral blood stem cell transplantation, allogeneic hematopoietic stem cell transplantation, cyclosporine, mycophenolate mofetil
- Biological · Radiation · Procedure + 1 more
- Lead sponsor
- Joseph Tuscano
- Other
- Eligibility
- 19 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Nemtabrutinib, Positron Emission Tomography and Computed Tomography Scan, Rituximab
- Procedure · Drug · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Duarte, California • Irvine, California
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,604 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Lymphoma
- Interventions
- rituximab, bortezomib, carboplatin, dexamethasone, etoposide, ifosfamide, polymerase chain reaction, western blotting
- Biological · Drug · Genetic
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 17
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 12 more
- Conditions
- Refractory Chronic Lymphocytic Leukemia
- Interventions
- Rituximab
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 21 Years to 99 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Obinutuzumab, Glofitamab, Pirtobrutinib, Tumor Imaging, Biospecimen Collection, ClonoSeq Assay, Bone Marrow Biopsy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- Davis, California • Los Angeles, California • San Diego, California + 1 more